Paper29948616
IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.
Vuletić A and 6 others. Pathol Oncol Res, 2020. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients. Papers, record 29948616. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29948616
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Interleukin-15 | Major topic |
| Interleukin-2 | Major topic |
| Lymph Nodes | Major topic |
| Lymphocyte Subsets | Major topic |
| Melanoma | Major topic |
| Skin Neoplasms | Major topic |
| CD8-Positive T-Lymphocytes | |
| Female | |
| Humans | |
| Killer Cells, Natural | |
| Male | |
| NK Cell Lectin-Like Receptor Subfamily K | |
| Natural Killer T-Cells | |
| Receptors, KIR2DL1 | |
| Receptors, KIR2DL3 | |
| Cutaneous Malignant Melanoma |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17953420 | Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. | Cancer Treat Res | 2007 | https://conductscience.org/library/papers/17953420 | PubMed |
| 2 | 20956026 | IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. | Immunobiology | 2011 | https://conductscience.org/library/papers/20956026 | PubMed |
| 3 | 19711124 | Distribution of several activating and inhibitory receptors on CD3-CD16+ NK cells and their correlation with NK cell function in healthy individuals. | J Membr Biol | 2009 | https://conductscience.org/library/papers/19711124 | PubMed |
| 4 | 21212348 | Innate or adaptive immunity? The example of natural killer cells. | Science | 2011 | https://conductscience.org/library/papers/21212348 | PubMed |
| 5 | 25380182 | In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15. | Melanoma Res | 2015 | https://conductscience.org/library/papers/25380182 | PubMed |
| 6 | 21467299 | Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. | Sci Signal | 2011 | https://conductscience.org/library/papers/21467299 | PubMed |
| 7 | 1692763 | Lymphocyte subset alterations in nodes regional to human melanoma. | Cancer Res | 1990 | https://conductscience.org/library/papers/1692763 | PubMed |
| 8 | 20172016 | Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. | Exp Hematol | 2010 | https://conductscience.org/library/papers/20172016 | PubMed |
| 9 | 18280748 | Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. | Cytokine | 2008 | https://conductscience.org/library/papers/18280748 | PubMed |
| 10 | 18713998 | Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors. | J Immunol | 2008 | https://conductscience.org/library/papers/18713998 | PubMed |
| 11 | 20693852 | Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. | Cancer J | 2010 | https://conductscience.org/library/papers/20693852 | PubMed |
| 12 | 25472612 | Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. | Nat Commun | 2014 | https://conductscience.org/library/papers/25472612 | PubMed |
| 13 | 18657862 | NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. | Mol Immunol | 2008 | https://conductscience.org/library/papers/18657862 | PubMed |
| 14 | 22349515 | Melanoma-induced immunosuppression and its neutralization. | Semin Cancer Biol | 2012 | https://conductscience.org/library/papers/22349515 | PubMed |
| 15 | 26597610 | Common gamma chain cytokines in combinatorial immune strategies against cancer. | Immunol Lett | 2016 | https://conductscience.org/library/papers/26597610 | PubMed |
| 16 | 26374324 | Natural killer cell receptors: alterations and therapeutic targeting in malignancies. | Immunol Res | 2016 | https://conductscience.org/library/papers/26374324 | PubMed |
| 17 | 14698281 | The double life of NK receptors: stimulation or co-stimulation? | Trends Immunol | 2004 | https://conductscience.org/library/papers/14698281 | PubMed |
| 18 | 21898152 | Regulation of immune cell function and differentiation by the NKG2D receptor. | Cell Mol Life Sci | 2011 | https://conductscience.org/library/papers/21898152 | PubMed |
| 19 | 9774227 | Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. | Naunyn Schmiedebergs Arch Pharmacol | 1998 | https://conductscience.org/library/papers/9774227 | PubMed |
| 20 | 11504744 | Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. | J Clin Oncol | 2001 | https://conductscience.org/library/papers/11504744 | PubMed |
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42968599 | Immunogenetic Signature of the MICA-129 Val/Val Genotype Associated With Metastasis in Melanoma. | J Immunol Res | 2026 | https://conductscience.org/library/papers/42968599 | PubMed |
| 41346595 | Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/41346595 | PubMed |
| 40636453 | The Multifaceted Role of the IL-2 Cytokine Family in Melanoma: Mechanisms, Therapeutic Implications, and Immune Modulation. | J Immunol Res | 2025 | https://conductscience.org/library/papers/40636453 | PubMed |
| 39907091 | Evaluating Predictors of Quality in Liver NK Cells Among Deceased Donors. | Cell Transplant | 2024 | https://conductscience.org/library/papers/39907091 | PubMed |
| 39628491 | Molecular cloning, expression analysis, and functional characterization of an interleukin-15 like gene in common carp (Cyprinus carpio L.). | Front Immunol | 2024 | https://conductscience.org/library/papers/39628491 | PubMed |
| 38506480 | Cancer immunity by tissue-resident type 1 innate lymphoid cells and killer innate-like T cells. | Immunol Rev | 2024 | https://conductscience.org/library/papers/38506480 | PubMed |
| 38255242 | Mice Generated with Induced Pluripotent Stem Cells Derived from Mucosal-Associated Invariant T Cells. | Biomedicines | 2024 | https://conductscience.org/library/papers/38255242 | PubMed |
| 38106519 | Suppression of NK Cell Activation by JAK3 Inhibition: Implication in the Treatment of Autoimmune Diseases. | J Immunol Res | 2023 | https://conductscience.org/library/papers/38106519 | PubMed |
| 37949944 | Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. | Cancer Gene Ther | 2023 | https://conductscience.org/library/papers/37949944 | PubMed |
| 37696894 | Double-edged sword: γδ T cells in mucosal homeostasis and disease. | Exp Mol Med | 2023 | https://conductscience.org/library/papers/37696894 | PubMed |
| 37626875 | Reduction of Ca2+ Entry by a Specific Block of KCa3.1 Channels Optimizes Cytotoxic Activity of NK Cells against T-ALL Jurkat Cells. | Cells | 2023 | https://conductscience.org/library/papers/37626875 | PubMed |
| 37221555 | Targeting oral tumor microenvironment for effective therapy. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/37221555 | PubMed |
| 37086778 | Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression. | J Adv Res | 2024 | https://conductscience.org/library/papers/37086778 | PubMed |
| 36936961 | The application of Interleukin-2 family cytokines in tumor immunotherapy research. | Front Immunol | 2023 | https://conductscience.org/library/papers/36936961 | PubMed |
| 36769064 | Natural Killer T-like Cells: Immunobiology and Role in Disease. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36769064 | PubMed |
| 36686835 | Contribution of natural killer cells in innate immunity against colorectal cancer. | Front Oncol | 2022 | https://conductscience.org/library/papers/36686835 | PubMed |
| 36590594 | IL-15 induced bystander activation of CD8+ T cells may mediate endothelium injury through NKG2D in Hantaan virus infection. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36590594 | PubMed |
| 35765872 | Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used. | Ann Lab Med | 2022 | https://conductscience.org/library/papers/35765872 | PubMed |
| 35378905 | The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs). | J Immunol Res | 2022 | https://conductscience.org/library/papers/35378905 | PubMed |
| 33467134 | EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33467134 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| IL15 | 3600 | PubTator's text mining | https://conductscience.org/library/genes/3600 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| KIR2DL2 | 3803 | PubTator's text mining | https://conductscience.org/library/genes/3803 | NCBI Gene |
| KIR2DS1 | 3806 | PubTator's text mining | https://conductscience.org/library/genes/3806 | NCBI Gene |
| KLRK1 | 22914 | PubTator's text mining | https://conductscience.org/library/genes/22914 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29948616
GET https://conductscience.org/api/papers/v1/29948616/references?page=2